Wheat L Joseph, Freifeld Alison G, Kleiman Martin B, Baddley John W, McKinsey David S, Loyd James E, Kauffman Carol A
MiraVista Diagnostics/MiraBella Technologies, Indianapolis, IN 46241, USA.
Clin Infect Dis. 2007 Oct 1;45(7):807-25. doi: 10.1086/521259. Epub 2007 Aug 27.
Evidence-based guidelines for the management of patients with histoplasmosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 30:688-95). The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. Since 2000, several new antifungal agents have become available, and clinical trials and case series have increased our understanding of the management of histoplasmosis. Advances in immunosuppressive treatment for inflammatory disorders have created new questions about the approach to prevention and treatment of histoplasmosis. New information, based on publications from the period 1999-2006, are incorporated into this guideline document. In addition, the panel added recommendations for management of histoplasmosis in children for those aspects that differ from aspects in adults.
美国传染病学会的一个专家小组制定了组织胞浆菌病患者管理的循证指南。这些更新后的指南取代了2000年发布的先前治疗指南(《临床传染病》2000年;30:688 - 95)。这些指南供照料患有这些感染或可能有感染风险患者的医护人员使用。自2000年以来,几种新的抗真菌药物已可供使用,并且临床试验和病例系列增加了我们对组织胞浆菌病管理的认识。炎症性疾病免疫抑制治疗的进展对组织胞浆菌病的预防和治疗方法产生了新问题。基于1999 - 2006年期间发表的文献的新信息被纳入本指南文件。此外,该小组针对儿童组织胞浆菌病管理中与成人不同的方面增加了建议。